TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Backgrounds/Aims: Transmembrane 6 superfamily member 2 (TM6SF2) E167K variant is closely associated with the occurrence and development of metabolic dysfunction-associated steatotic liver disease (MASLD). However, the role and mechanism of TM6SF2 E167K variant during MASLD progression are not yet fully understood. Methods: The Tm6sf2167K knock-in (KI) mice were subjected to high-fat diet (HFD). Hepatic lipid levels of Tm6sf2167K KI mice were detected by lipidomics analysis. Thin-layer chromatography (TLC) was used to measure the newly synthesized triglyceride (TG) and phosphatidylcholine (PC). Results: The TM6SF2 E167K variant significantly aggravated hepatic steatosis and injury in HFD-induced mice. Decreased polyunsaturated PC level and increased polyunsaturated TG level were found in liver tissue of HFDinduced Tm6sf2167K KI mice. Mechanistic studies demonstrated that the TM6SF2 E167K variant increased the interaction between TM6SF2 and PNPLA3, and impaired PNPLA3-mediated transfer of polyunsaturated fatty acids (PUFAs) from TG to PC. The TM6SF2 E167K variant increased the level of fatty acid-induced malondialdehyde and reactive oxygen species, and decreased fatty acid-downregulated cell membrane fluidity. Additionally, the TM6SF2 E167K variant decreased the level of hepatic PC containing C18:3, and dietary supplementation of PC containing C18:3 significantly attenuated the TM6SF2 E167K-induced hepatic steatosis and injury in HFD-fed mice. Conclusions: The TM6SF2 E167K variant could promote its interaction with PNPLA3 and inhibit PNPLA3-mediated transfer of PUFAs from TG to PC, resulting in the hepatic steatosis and injury during MASLD progression. PC containing C18:3 could act as a potential therapeutic supplement for MASLD patients carrying the TM6SF2 E167K variant.
Abstract
Backgrounds/Aims: Transmembrane 6 superfamily member 2 (TM6SF2) E167K variant is closely associated with the occurrence and development of metabolic dysfunction-associated steatotic liver disease (MASLD). However, the role and mechanism of TM6SF2 E167K variant during MASLD progression are not yet fully understood. Methods: The Tm6sf2167K knock-in (KI) mice were subjected to high-fat diet (HFD). Hepatic lipid levels of Tm6sf2167K KI mice were detected by lipidomics analysis. Thin-layer chromatography (TLC) was used to measure the newly synthesized triglyceride (TG) and phosphatidylcholine (PC). Results: The TM6SF2 E167K variant significantly aggravated hepatic steatosis and injury in HFD-induced mice. Decreased polyunsaturated PC level and increased polyunsaturated TG level were found in liver tissue of HFDinduced Tm6sf2167K KI mice. Mechanistic studies demonstrated that the TM6SF2 E167K variant increased the interaction between TM6SF2 and PNPLA3, and impaired PNPLA3-mediated transfer of polyunsaturated fatty acids (PUFAs) from TG to PC. The TM6SF2 E167K variant increased the level of fatty acid-induced malondialdehyde and reactive oxygen species, and decreased fatty acid-downregulated cell membrane fluidity. Additionally, the TM6SF2 E167K variant decreased the level of hepatic PC containing C18:3, and dietary supplementation of PC containing C18:3 significantly attenuated the TM6SF2 E167K-induced hepatic steatosis and injury in HFD-fed mice. Conclusions: The TM6SF2 E167K variant could promote its interaction with PNPLA3 and inhibit PNPLA3-mediated transfer of PUFAs from TG to PC, resulting in the hepatic steatosis and injury during MASLD progression. PC containing C18:3 could act as a potential therapeutic supplement for MASLD patients carrying the TM6SF2 E167K variant.
참고문헌 (45)
- Rinella ME, "A multisociety Delphi consensus statement on new fatty liver disease nomenclature", J Hepatol, 79, pp.1542~1556 (2023)
- Sheka AC, "Nonalcoholic steatohepatitis : A review", JAMA, 323, pp.1175~1183 (2020)
- Le MH, "Global incidence of non-alcoholic fatty liver disease : A systematic review and meta-analysis of 63 studies and 1, 201, 807 persons", J Hepatol, 79, pp.287~295 (2023)
- Wong RJ, "Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States", Gastroenterology, 148, pp.547~555 (2015)
- Stefan N, "Non-alcoholic fatty liver disease : causes, diagnosis, cardiometabolic consequences, and treatment strategies", Lancet Diabetes Endocrinol, 7, pp.313~324 (2019)
- Diehl AM, "Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis", N Engl J Med, 377, pp.2063~2072 (2017)
- Friedman SL, "Mechanisms of NAFLD development and therapeutic strategies", Nat Med, 24, pp.908~922 (2018)
- Kozlitina J, "Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 46, pp.352~356 (2014)
- Sookoian S, "Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity", Hepatology, 61, pp.515~525 (2015)
- Yang J, "PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases", Int J Cancer, 144, pp.533~544 (2019)
- Mahdessian H, "TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content", Proc Natl Acad Sci U S A, 111, pp.8913~8918 (2014)
- Ehrhardt N, "Hepatic Tm6sf2 overexpression affects cellular ApoBtrafficking, plasma lipid levels, hepatic steatosis and atherosclerosis", Hum Mol Genet, 26, pp.2719~2731 (2017)
- Newberry EP, "Liver-specific deletion of mouse Tm6sf2 promotes steatosis, fibrosis, and hepatocellular cancer", Hepatology, 74, pp.1203~1219 (2021)
- Fan Y, "Type 2 diabetes sex-specific effects associated with E167K coding variant in TM6SF2", iScience, 24, pp.103196~ (2021)
- Li BT, "Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease", PLoS Genet, 16, pp.e1008955~ (2020)
- Fan Y, "Hepatic transmembrane 6 superfamily member 2 regulates cholesterol metabolism in mice", Gastroenterology, 150, pp.1208~1218 (2016)
- Luukkonen PK, "Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD", J Hepatol, 67, pp.128~136 (2017)
- Chin CF, "Blood-derived lysophospholipid sustains hepatic phospholipids and fat storage necessary for hepatoprotection in overnutrition", J Clin Invest, 133, pp.e171267~ (2023)
- van der Veen JN, "The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease", Biochim Biophys Acta Biomembr, 1859, pp.1558~1572 (2017)
- Cole LK, "Phosphatidylcholine biosynthesis and lipoprotein metabolism", Biochim Biophys Acta, 1821, pp.754~761 (2012)
- Vance DE, "Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis", Curr Opin Lipidol, 19, pp.229~234 (2008)
- Yao ZM, "The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes", J Biol Chem, 263, pp.2998~3004 (1988)
- Fast DG, "Nascent VLDL phospholipid composition is altered when phosphatidylcholine biosynthesis is inhibited : evidence for a novel mechanism that regulates VLDL secretion", Biochim Biophys Acta, 1258, pp.159~168 (1995)
- Mitsche MA, "Patatin-like phospholipase domain–containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets", J Biol Chem, 293, pp.6958~6968 (2018)
- Jenkins CM, "Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2family members possessing triacylglycerol lipase and acylglycerol transacylase activities", J Biol Chem, 279, pp.48968~48975 (2004)
- Luukkonen PK, "Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids", JCI Insight, 4, pp.e127902~ (2019)
- Okiyama W, "Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress", J Hepatol, 50, pp.1236~1246 (2009)
- Aparicio-Vergara M, "Isolation of kupffer cells and hepatocytes from a single mouse liver", Methods Mol Biol, 1639, pp.161~171 (2017)
- Liu J, "Advanced method for isolation of mouse hepatocytes, liver sinusoidal endothelial cells, and Kupffer cells", Methods Mol Biol, 1540, pp.249~258 (2017)
- Sherman DJ, "The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics", Proc Natl Acad Sci U S A, 121, pp.e2318619121~ (2024)
- Lawrence GD, "Perspective : The saturated fat-unsaturated oil dilemma : Relations of dietary fatty acids and serum cholesterol, atherosclerosis, inflammation, cancer, and all-cause mortality", Adv Nutr, 12, pp.647~656 (2021)
- Fromenty B, "The ins and outs of mitochondrial dysfunction in NASH", Diabetes Metab, 30, pp.121~138 (2004)
- Zhao J, "Electron transfer-based antioxidant nanozymes : Emerging therapeutics for inflammatory diseases", J Control Release, 355, pp.273~291 (2023)
- Prill S, "The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids", Sci Rep, 9, pp.11585~ (2019)
- Smagris E, "Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis", Hepatology, 61, pp.108~118 (2015)
- Pingitore P, "Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function", Biochim Biophys Acta, 1841, pp.574~580 (2014)
- BasuRay S, "Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis", Proc Natl Acad Sci U S A, 116, pp.9521~9526 (2019)
- Seko Y, "Differential effects of genetic polymorphism on comorbid disease in metabolic dysfunction-associated steatotic liver disease", Clin Gastroenterol Hepatol, 22, pp.1436~1443 (2024)
- Paternostro R, "Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease", Hepatol Int, 15, pp.922~933 (2021)
- Liu YL, "TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease", Nat Commun, 5, pp.4309~ (2014)
- Day CP, "Steatohepatitis : a tale of two"hits"?", Gastroenterology, 114, pp.842~845 (1998)
- Masarone M, "Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease", Oxid Med Cell Longev, 2018, pp.9547613~ (2018)
- Li X, "Protective effects of polyenoylphosphatidylcholine in rats with severe acute pancreatitis", Pancreas, 44, pp.596~601 (2015)
- Mak KM, "Soybean polyenylphosphatidylcholine(PPC)is beneficial in liver and extrahepatic tissue injury : An update in experimental research", Anat Rec(Hoboken), 307, pp.2162~2186 (2024)
- Hashidate-Yoshida T, "Fatty acid remodeling by LPCAT3enriches arachidonate in phospholipid membranes and regulates triglyceride transport", Elife, 4, pp.e06328~ (2015)